Surmodics, Inc.

SRDX · NASDAQ Global Select · USD

42,98USD

+0,15 (+0,35 %)Stand 25. Nov., 14:30

Vortag 42,98

Kennzahlen

Eröffnung
42,98
Vortag
42,98
Tagesspanne
42,98 – 42,98
52 Wochen
25,87 – 43,00
Volumen
5,34 Mio.
Ø Volumen
435.959
Börsenwert
614,51 Mio. $
KGV
–
Gewinn je Aktie (TTM)
–
Dividendenrendite
–
Beta
1,4
Nächste Zahlen
–

Finanzen

Gerade nicht verfügbar.

Bewertung

Gerade nicht verfügbar.

Analysten

Einstufungen

Gerade nicht verfügbar.

Kursziel

Gerade nicht verfügbar.

Quartalszahlen

Gerade nicht verfügbar.

Dividenden und Splits

Gerade nicht verfügbar.

Aktiensplits

Gerade nicht verfügbar.

Eigentümer

Institutionen

Gerade nicht verfügbar.

Insider-Geschäfte

Gerade nicht verfügbar.

Vergleichbare Unternehmen

Gerade nicht verfügbar.

Über das Unternehmen

Surmodics, Inc., together with its affiliates, specializes in providing advanced surface modification solutions tailored for intravascular medical devices. Additionally, the company supplies specialized chemical components essential for in vitro diagnostic immunoassay tests and microarrays. Its operations span both the United States and international markets. The company is structured into two primary divisions: Medical Device and In Vitro Diagnostics (IVD). Within the Medical Device segment, Surmodics offers innovative coating technologies that are engineered to improve the accessibility, maneuverability, and reliable deployment of medical devices. This segment also develops drug-delivery coating systems, enabling precise, localized therapeutic release directly from a device's surface for applications in various areas, including coronary, peripheral, neuro-vascular, and structural heart procedures. Moreover, this division is involved in the design, development, and manufacturing of interventional medical instruments, notably balloons and catheters, including drug-coated balloons utilized in the treatment of peripheral arterial disease and other conditions. The IVD segment focuses on creating and producing foundational component products and technologies for diagnostic immunoassay, molecular testing, and biomedical research. Its portfolio in this area includes protein stabilization reagents, specialized substrates, surface coatings, and antigens. Surmodics was established in 1979 and maintains its corporate headquarters in Eden Prairie, Minnesota.

CEO
Gary R. Maharaj
Mitarbeitende
389
Hauptsitz
Eden Prairie, MN, US
Sektor
Healthcare
Branche
Medical - Devices
Börsengang
4. März 1998

Nachrichten

Gerade nicht verfügbar.

Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.